Efficacy of combination therapy with probiotics and mosapride in patients with IBS without diarrhea: a randomized, double-blind, placebo-controlled, multicenter, phase II trial
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Choi, C. H. | - |
dc.contributor.author | Kwon, J. G. | - |
dc.contributor.author | Kim, S. K. | - |
dc.contributor.author | Myung, S. -J. | - |
dc.contributor.author | Park, K. S. | - |
dc.contributor.author | Sohn, C. -I. | - |
dc.contributor.author | Rhee, P. -L. | - |
dc.contributor.author | Lee, K. J. | - |
dc.contributor.author | Lee, O. Y. | - |
dc.contributor.author | Jung, H. -K. | - |
dc.contributor.author | Jee, S. R. | - |
dc.contributor.author | Jeen, Y. T. | - |
dc.contributor.author | Choi, M. -G. | - |
dc.contributor.author | Choi, S. C. | - |
dc.contributor.author | Huh, K. C. | - |
dc.contributor.author | Park, H. | - |
dc.date.accessioned | 2021-09-04T16:21:44Z | - |
dc.date.available | 2021-09-04T16:21:44Z | - |
dc.date.created | 2021-06-18 | - |
dc.date.issued | 2015-05 | - |
dc.identifier.issn | 1350-1925 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/93643 | - |
dc.description.abstract | Background Probiotics can be beneficial in irritable bowel syndrome (IBS). Mosapride citrate, a selective 5-HT4 receptor agonist, stimulates gastrointestinal motility. We investigated the efficacy of combination therapy with probiotics and mosapride for non-diarrheal-type IBS. Methods Two hundred and eighty-five IBS patients were randomly assigned to either a combination of probiotics (Bacillus subtilis and Streptococcus faecium) and mosapride at one of four different doses or a placebo for 4 weeks. The primary outcome was the proportion of patients experiencing adequate relief (AR) of global IBS symptoms at week 4. The secondary outcomes included subject's global assessment (SGA) of IBS symptom relief, individual symptoms, stool parameters, and IBS-quality of life. Key Results The proportion of AR at week 4 was significantly higher in all treatment groups compared to the placebo group (53.7% in group 1, 55.0% in group 2, 55.2% in group 3, 53.6% in group 4 [the highest dose], and 35.1% in placebo group, respectively, p < 0.05). The proportion of patients reporting 'completely or considerably relieved' in the SGA was higher in the treatment groups than in the placebo group. The abdominal pain/discomfort score in the treatment group 4 was more prominently improved compared with that of the placebo group. In patients with constipation-predominant IBS, the improvements in stool frequency and consistency were significantly higher in the treatment groups 4 and 1, respectively, than those in the placebo group. Conclusions & Inferences Combination therapy with probiotics and mosapride is effective for relief of symptoms in patients with non-diarrheal-type IBS. The study has been registered in the US National Library of Medicine (http://www.clinicaltrials.gov, NCT01505777). | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | WILEY | - |
dc.subject | IRRITABLE-BOWEL-SYNDROME | - |
dc.subject | FUNCTIONAL GASTROINTESTINAL DISORDERS | - |
dc.subject | QUALITY-OF-LIFE | - |
dc.subject | INTESTINAL MICROBIOTA | - |
dc.subject | CHRONIC CONSTIPATION | - |
dc.subject | GUT MICROBIOTA | - |
dc.subject | CLINICAL-TRIAL | - |
dc.subject | FECAL MICROBIOTA | - |
dc.subject | FERMENTED MILK | - |
dc.subject | IN-VITRO | - |
dc.title | Efficacy of combination therapy with probiotics and mosapride in patients with IBS without diarrhea: a randomized, double-blind, placebo-controlled, multicenter, phase II trial | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Jeen, Y. T. | - |
dc.identifier.doi | 10.1111/nmo.12544 | - |
dc.identifier.scopusid | 2-s2.0-84928195784 | - |
dc.identifier.wosid | 000364742000013 | - |
dc.identifier.bibliographicCitation | NEUROGASTROENTEROLOGY AND MOTILITY, v.27, no.5, pp.705 - 716 | - |
dc.relation.isPartOf | NEUROGASTROENTEROLOGY AND MOTILITY | - |
dc.citation.title | NEUROGASTROENTEROLOGY AND MOTILITY | - |
dc.citation.volume | 27 | - |
dc.citation.number | 5 | - |
dc.citation.startPage | 705 | - |
dc.citation.endPage | 716 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Gastroenterology & Hepatology | - |
dc.relation.journalResearchArea | Neurosciences & Neurology | - |
dc.relation.journalWebOfScienceCategory | Gastroenterology & Hepatology | - |
dc.relation.journalWebOfScienceCategory | Clinical Neurology | - |
dc.relation.journalWebOfScienceCategory | Neurosciences | - |
dc.subject.keywordPlus | IRRITABLE-BOWEL-SYNDROME | - |
dc.subject.keywordPlus | FUNCTIONAL GASTROINTESTINAL DISORDERS | - |
dc.subject.keywordPlus | QUALITY-OF-LIFE | - |
dc.subject.keywordPlus | INTESTINAL MICROBIOTA | - |
dc.subject.keywordPlus | CHRONIC CONSTIPATION | - |
dc.subject.keywordPlus | GUT MICROBIOTA | - |
dc.subject.keywordPlus | CLINICAL-TRIAL | - |
dc.subject.keywordPlus | FECAL MICROBIOTA | - |
dc.subject.keywordPlus | FERMENTED MILK | - |
dc.subject.keywordPlus | IN-VITRO | - |
dc.subject.keywordAuthor | irritable bowel syndrome | - |
dc.subject.keywordAuthor | mosapride | - |
dc.subject.keywordAuthor | probiotics | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.